EP2415749A4 - Neue salvianolsäureverbindung l, zubereitungsverfahren und verwendung - Google Patents

Neue salvianolsäureverbindung l, zubereitungsverfahren und verwendung

Info

Publication number
EP2415749A4
EP2415749A4 EP10758037A EP10758037A EP2415749A4 EP 2415749 A4 EP2415749 A4 EP 2415749A4 EP 10758037 A EP10758037 A EP 10758037A EP 10758037 A EP10758037 A EP 10758037A EP 2415749 A4 EP2415749 A4 EP 2415749A4
Authority
EP
European Patent Office
Prior art keywords
salvianolic acid
preparation
acid compound
new
new salvianolic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP10758037A
Other languages
English (en)
French (fr)
Other versions
EP2415749B1 (de
EP2415749A1 (de
Inventor
Shuiping Zhou
Wei Li
Yuanpeng Jin
Xiaohui Ma
Jianping Han
Hongfang Cui
Xuejun Luo
Xiaopeng Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tasly Pharmaceutical Group Co Ltd
Original Assignee
Tasly Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tasly Pharmaceutical Group Co Ltd filed Critical Tasly Pharmaceutical Group Co Ltd
Publication of EP2415749A1 publication Critical patent/EP2415749A1/de
Publication of EP2415749A4 publication Critical patent/EP2415749A4/de
Application granted granted Critical
Publication of EP2415749B1 publication Critical patent/EP2415749B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP10758037.5A 2009-03-30 2010-03-29 Neue salvianolsäureverbindung l, zubereitungsverfahren und verwendung Active EP2415749B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200910068289 2009-03-30
PCT/CN2010/071388 WO2010111935A1 (zh) 2009-03-30 2010-03-29 一种新的丹酚酸化合物l、其制备方法和用途

Publications (3)

Publication Number Publication Date
EP2415749A1 EP2415749A1 (de) 2012-02-08
EP2415749A4 true EP2415749A4 (de) 2012-12-12
EP2415749B1 EP2415749B1 (de) 2016-05-04

Family

ID=42827489

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10758037.5A Active EP2415749B1 (de) 2009-03-30 2010-03-29 Neue salvianolsäureverbindung l, zubereitungsverfahren und verwendung

Country Status (11)

Country Link
US (1) US20120041062A1 (de)
EP (1) EP2415749B1 (de)
JP (1) JP5755633B2 (de)
KR (1) KR20120006029A (de)
AU (1) AU2010230770B2 (de)
CA (1) CA2756823C (de)
HK (1) HK1168584A1 (de)
MY (1) MY183588A (de)
RU (1) RU2529491C2 (de)
SG (1) SG174548A1 (de)
WO (1) WO2010111935A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102600420A (zh) * 2012-04-01 2012-07-25 李承平 一组血瘀气滞药物组合
WO2015003659A1 (zh) * 2013-07-11 2015-01-15 天士力制药集团股份有限公司 一种中药组合物及其制剂和用途
TWI621443B (zh) 2013-07-11 2018-04-21 Tasly Pharmaceutical Group Co Ltd 中藥組合物及其用途、包含該中藥組合物之藥物製劑及複方丹參微滴丸劑、及該微滴丸劑的製備方法
EP3020395B1 (de) 2013-07-11 2021-03-03 Tasly Pharmaceutical Group Co., Ltd. Verfahren zur herstellung einer mikrotropfenpille nach art der traditionellen chinesischen medizin sowie in diesem verfahren hergestellte mikrotropfenpille nach art der traditionellen chinesischen medizin
AU2014314774B2 (en) * 2013-08-29 2019-04-18 Tasly Pharmaceutical Group Co., Ltd. Traditional Chinese medicine composition
CN104418744B (zh) * 2013-08-29 2017-03-01 天士力制药集团股份有限公司 一种新的丹酚酸化合物t、其制备方法和用途
CN104434899A (zh) * 2013-09-24 2015-03-25 天士力制药集团股份有限公司 丹酚酸l在制备治疗或预防肝纤维化和肾纤维化的药物中的应用
CN105085267A (zh) * 2014-05-21 2015-11-25 天津国际生物医药联合研究院 丹酚酸a的合成方法
US10170953B2 (en) 2015-10-02 2019-01-01 E-Circuit Motors, Inc. Planar composite structures and assemblies for axial flux motors and generators
US9800109B2 (en) 2015-10-02 2017-10-24 E-Circuit Motors, Inc. Structures and methods for controlling losses in printed circuit boards
US11527933B2 (en) 2015-10-02 2022-12-13 E-Circuit Motors, Inc. Stator and rotor design for periodic torque requirements
US9673684B2 (en) 2015-10-02 2017-06-06 E-Circuit Motors, Inc. Structures and methods for thermal management in printed circuit board stators
US9673688B2 (en) 2015-10-02 2017-06-06 E-Circuit Motors, Inc. Apparatus and method for forming a magnet assembly
US9859763B2 (en) 2015-10-02 2018-01-02 E-Circuit Motors, Inc. Structures and methods for controlling losses in printed circuit boards
US11121614B2 (en) 2017-06-05 2021-09-14 E-Circuit Motors, Inc. Pre-warped rotors for control of magnet-stator gap in axial flux machines
CN105461543A (zh) * 2015-12-22 2016-04-06 贵州景峰注射剂有限公司 一种将丹参素转化成丹参素钠的方法
CN105566092A (zh) * 2015-12-22 2016-05-11 贵州景峰注射剂有限公司 一种高含量丹参素钠的制备方法
US11831211B2 (en) 2017-06-05 2023-11-28 E-Circuit Motors, Inc. Stator and rotor design for periodic torque requirements
US11005322B2 (en) 2017-06-05 2021-05-11 E-Circuit Motors, Inc. Rotor assemblies for axial flux machines
CN110274962B (zh) * 2018-03-13 2022-10-18 天士力医药集团股份有限公司 一种芪参益气滴丸中丹参多酚酸成分含量测定方法
CN109748793B (zh) * 2018-12-29 2021-07-09 正大青春宝药业有限公司 一种去除丹酚酸a钠中异丹酚酸a1和异丹酚酸a2的方法
CN110563677B (zh) * 2019-08-23 2022-06-24 惠州市九惠制药股份有限公司 一种丹酚酸b及其粉雾剂胶囊和制备方法
WO2021063366A1 (zh) 2019-09-30 2021-04-08 中国科学院上海药物研究所 用于治疗动脉相关疾病的药物及其用途
CN110642735A (zh) * 2019-10-14 2020-01-03 南华大学 一种丹酚酸a类似物及其作为抗氧化剂的用途
CN111732617B (zh) * 2020-06-29 2024-02-27 中国科学院西北高原生物研究所 新黄酮类化合物Hyd的提取方法
CN111714488A (zh) * 2020-07-07 2020-09-29 张维 一种二元药物组合物、胶囊药物、片剂药物及其应用
CN114075158B (zh) * 2020-08-19 2023-12-15 西安碑林药业股份有限公司 丹参素和丹酚酸b含量的提取和检测方法
AU2022223244A1 (en) 2021-02-17 2023-08-10 E-Circuit Motors, Inc. Planar stator configurations for axial flux machines
CN113214157A (zh) * 2021-04-25 2021-08-06 广西壮族自治区花红药业集团股份公司 吡咯烷酮类化合物在制备治疗炎症性疾病的药物中的用途
KR20240077490A (ko) 2021-07-30 2024-05-31 이-서킷 모터스 인코퍼레이티드 자성 물질 충전된 인쇄 회로 기판 및 인쇄 회로 기판 고정자
US11336130B1 (en) 2021-08-17 2022-05-17 E-Circuit Motors, Inc. Low-loss planar winding configurations for an axial flux machine
CN113968774B (zh) * 2021-11-23 2024-01-30 辽宁中医药大学 马齿苋中一种多芳基化合物及其提取分离方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1741439A1 (de) * 2004-03-17 2007-01-10 Tianjin Tasly Pharmaceutical Co., Ltd. Traditionelles chinesisches medizinpräparat für kardiozerebrale blutgefässerkrankungen und sein herstellungsverfahren

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02131423A (ja) * 1988-07-08 1990-05-21 Terumo Corp ５−リポキシゲナーゼ作用阻害剤
US6037369A (en) * 1998-06-25 2000-03-14 Georgetown University School Of Medicine Compounds obtained from salvia species having antiviral Activity
US6043276A (en) * 1998-06-25 2000-03-28 Georgetown University School Of Medicine Compounds obtained from salvia species having antiviral activity
US8486464B2 (en) * 2000-12-22 2013-07-16 Tasly Pharmaceutical Group Co. Ltd. Herbal composition for angina pectoris, method to prepare same and uses thereof
CN1378837A (zh) * 2001-04-09 2002-11-13 中国医学科学院药物研究所 丹参丹酚酸类化合物在制药中的应用
CN1202103C (zh) * 2002-05-23 2005-05-18 天津天士力制药股份有限公司 丹参总酚酸的制备方法
EP1371368A1 (de) * 2002-06-11 2003-12-17 N.V. Nutricia Salvianolsäurederivaten als Lipaseinhibitoren
US20070071837A1 (en) * 2003-08-28 2007-03-29 Tianjin Tasly Pharmaceutical Co., Ltd. Treatment of aspirin resistance with radix salviae mitiorhizae, its extract and composition
CN100339085C (zh) * 2003-09-23 2007-09-26 天津天士力制药股份有限公司 治疗心脑血管疾病的中药组合物
CN1785284B (zh) * 2004-12-10 2012-04-18 天津天士力制药股份有限公司 一种含有何首乌的药物组合物
CN100457748C (zh) * 2006-10-18 2009-02-04 中国医学科学院医药生物技术研究所 一种酚酸类化合物丹酚酸n及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1741439A1 (de) * 2004-03-17 2007-01-10 Tianjin Tasly Pharmaceutical Co., Ltd. Traditionelles chinesisches medizinpräparat für kardiozerebrale blutgefässerkrankungen und sein herstellungsverfahren

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KELLEY C J ET AL: "Polyphenolic Acids of Lithospermum ruderale Dougl. ex Lehm. (Borginaceae). 1. Isolation and Structure Determination of Lithospermic Acid", JOURNAL OF ORGANIC CHEMISTRY, ACS, US, vol. 40, no. 12, 1 January 1975 (1975-01-01), pages 1804 - 1815, XP002204923, ISSN: 0022-3263, DOI: 10.1021/JO00900A028 *
See also references of WO2010111935A1 *

Also Published As

Publication number Publication date
RU2011139614A (ru) 2013-05-10
KR20120006029A (ko) 2012-01-17
AU2010230770B2 (en) 2014-07-03
EP2415749B1 (de) 2016-05-04
AU2010230770A1 (en) 2011-10-13
SG174548A1 (en) 2011-10-28
HK1168584A1 (zh) 2013-01-04
JP5755633B2 (ja) 2015-07-29
US20120041062A1 (en) 2012-02-16
MY183588A (en) 2021-02-27
CA2756823C (en) 2017-01-17
RU2529491C2 (ru) 2014-09-27
WO2010111935A1 (zh) 2010-10-07
CA2756823A1 (en) 2010-10-07
EP2415749A1 (de) 2012-02-08
JP2012522022A (ja) 2012-09-20

Similar Documents

Publication Publication Date Title
EP2415749A4 (de) Neue salvianolsäureverbindung l, zubereitungsverfahren und verwendung
MX2012008285A (es) Bloqueantes de los canales de sodio dependientes del voltaje.
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
BR112012012903A2 (pt) compostos de espiropiperidina
HK1163500A1 (en) Pharmaceutical composition for the treatment of heart diseases
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
MX349004B (es) Nuevos compuestos.
GB201118656D0 (en) New compounds
IN2012DN02805A (de)
EP2431366A4 (de) Neue konjugierte chlor-e6-folsäureverbindung, herstellungsverfahren dafür und pharmazeutische verbindung damit zur behandlung von krebs
TN2011000370A1 (en) Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
EA201491028A1 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
MX2014007897A (es) Nuevos derivados de azetidina, composiciones farmaceuticas y sus usos.
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
IN2012DN02139A (de)
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
TN2014000112A1 (en) Ep1 receptor ligands
MX2012002580A (es) Compuesto antibacteriano novedoso de hidroxifenilo.
IN2014DN03010A (de)
WO2012151464A3 (en) Use of radiographic contrast agents for detecting dental caries
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
EP2402342A4 (de) Pharmazeutische zusammensetzung zur behandlung von diabetes typ 2
MX2014000870A (es) Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina.
EP2563785A4 (de) Verbindungen als agonisten gegen s1p1-rezeptoren
TR201009166A2 (tr) Sefdinir içeren farmasötik bileşim için üretim yöntemi

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111019

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD.

A4 Supplementary search report drawn up and despatched

Effective date: 20121112

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 59/52 20060101AFI20121106BHEP

Ipc: C07C 51/42 20060101ALI20121106BHEP

Ipc: A61K 31/192 20060101ALI20121106BHEP

Ipc: A61P 9/00 20060101ALI20121106BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1168584

Country of ref document: HK

17Q First examination report despatched

Effective date: 20150608

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20151119

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 796770

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160515

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010033093

Country of ref document: DE

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20160504

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160504

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160504

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160804

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160504

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 796770

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160504

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160504

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160905

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160504

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160504

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160805

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1168584

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160504

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160504

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160504

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160504

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160504

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010033093

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160504

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160504

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160504

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160504

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

26N No opposition filed

Effective date: 20170207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160504

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160504

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170331

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170331

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170329

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20100329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160504

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160504

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160504

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160504

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160904

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230526

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240318

Year of fee payment: 15

Ref country code: GB

Payment date: 20240322

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20240321

Year of fee payment: 15

Ref country code: IT

Payment date: 20240329

Year of fee payment: 15

Ref country code: FR

Payment date: 20240320

Year of fee payment: 15